Johnson & Johnson's nipocalimab could become the first approved treatment for a blood disorder that can lead to the death of a foetus or newborn, if positive results i
Shares in Johnson & Johnson have come under pressure amid reports that an appeals court in the US has rejected the bankruptcy petition filed by a new company it formed
One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.
Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients o
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.